GlassScriptPhysician profile
Stephen D Lazar
NPI 1811990872
$492.31
in general payments reported to CMS, 2019-2025
12 companies · $15.81 in 2025
The $15.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $25.21 · 2021: $48.74 · 2022: $159 · 2023: $83.24 · 2024: $50.33 · 2025: $15.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $97.98 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $97.12 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $67.52 | 2022-2025 | |
| Amgen INC. | $62.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.84 | 2022-2023 | |
| Baxter Healthcare | $29.86 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $29.04 | 2022 | |
| Glaxosmithkline, LLC. | $23.00 | 2019 | |
| Esperion Therapeutics, INC. | $14.96 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 | |
| Amarin Pharma, INC. | $13.21 | 2020 | |
| Bardy Diagnostics, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.